Long-Term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures.
Pavel KleinSami AboumatarChristian BrandtFang DongGregory L KraussSarah MizneJuan Carlos Sanchez-AlvarezBernhard J SteinhoffVicente VillanuevaPublished in: Neurology (2022)
This study provides Class IV evidence that oral Cenobamate 50-400 mg/day is effective as an adjunctive treatment for the long-term management of patients with uncontrolled focal seizures previously treated with 1 to 3 ASMs.